BMS Gains Option to Acquire F-star Alpha and its HER2 Antibody Fragment in US$475 M Deal
By Heather Cartwright
Pharma Deals Review: Vol 2014 Issue 11 (Table of Contents)
Published: 12 Nov-2014
DOI: 10.3833/pdr.v2014.i11.2074 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Bristol-Myers Squibb (BMS), a prolific dealmaker in the immuno-oncology field, has agreed to pay US$50 M in upfront and near-term payments to secure an option to acquire F-star Alpha and its lead asset FS102, a Phase I-ready antibody fragment targeting human epidermal growth factor receptor 2 (HER2) for the treatment of HER2-positive breast and gastric cancers...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS